Theralink Technologies Inc.
OOTC:THER0.00
USD
0.00
(0.00%)
ISIN
US88339Q1094
CUSIP
88339Q109
Return %
Stock
S&P 500
1Y
0.00
14.20
3Y
-99.89
81.12
5Y
-100.00
68.34
Capital Structure
USD
•
in mil. unless spec.Working Capital
USD
•
in mil. unless spec.Growth Rates
USD
•
in mil. unless spec.Quarterly Revenue
USD
•
in mil. unless spec.Quarterly Earnings Per Share
USD
•
in mil. unless spec.Quarterly Dividends Per Share
USD
•
in mil. unless spec.Company Description
- CEO
- Michael I. Ruxin
- Full Time Employees
- 16
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- 15000 West 6th Avenue Golden CO United States 80401
- IPO Date
- Apr 23, 2007
- Website
- theralink.com
- Similar Companies
- Business
- Theralink Technologies, Inc. (THER) operates as a commercial-stage precision medicine and molecular data-generating company focused on proteomics-based diagnostics for oncology. The company develops and commercializes patented phosphoprotein and protein biomarker platforms along with laboratory-developed tests (LDTs) that target multiple areas of oncology and drug development; its core offerings include the Theralink Reverse Phase Protein Array (RPPA) assays, which provide precision oncology data to identify likely responders and non-responders to FDA-approved and investigational treatments, laser capture microdissection for tumor sample analysis, and the Theralink Assay for Breast Cancer to support targeted treatment decisions for patients with advanced breast cancer; these services also enable biopharmaceutical companies to accelerate drug discovery, evaluate drug target inhibition, and interrogate signaling pathways in preclinical and clinical samples. Theralink Technologies serves clinical oncologists, patients, and biopharma clients across the United States, with operations centered in the biotechnology and precision medicine sectors. Founded in 2005 and headquartered at 15000 West 6th Avenue, Suite 400, Golden, Colorado 80401, the company formerly operated as OncBioMune Pharmaceuticals, Inc. prior to changing its name to Theralink Technologies, Inc. in September 2020. In recent developments, IMAC Holdings, Inc. (Nasdaq: BACK) acquired key assets from Theralink in May 2024 through a settlement agreement, enabling the continuation and commercialization of its precision medicine technologies, including breast cancer diagnostics, while transitioning personnel to stabilize operations and resolve prior debt issues stemming from a terminated 2023 merger plan.
Company News
Theralink announces groundbreaking RPPA study by partner GMU - reveals novel therapy options for hard-to-treat breast cancer patients that could lead to significant improvements in response rates
Theralink® and IMAC Holdings announce receipt and response to the Securities and Exchange Commission comments on the previously filed Form S4
Theralink® Announces Promising Interim Results on the Implementation of Proteomic Analysis into Inova Schar Cancer Institute's Molecular Tumor Board
Theralink Announces Filing of Form S-4; Merger with IMAC Holdings Expected During Q4 2023